Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04563832
Registration number
NCT04563832
Ethics application status
Date submitted
21/09/2020
Date registered
24/09/2020
Date last updated
12/04/2022
Titles & IDs
Public title
Self-administered Hyperinsufflation Chest on the Risk of Low Respiratory Infection in Patients With Multiple Sclerosis With Sputum Capacity Deficit
Query!
Scientific title
Self-administered Hyperinsufflation Chest Mobilization Randomized Study on the Risk of Low Respiratory Infection in Patients With Multiple Sclerosis With Sputum Capacity Deficit
Query!
Secondary ID [1]
0
0
APHP2020
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
MS-COUGH
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Multiple Sclerosis
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Standardized respiratory management program
Other interventions - CoughAssist
Other: Control group - standardized respiratory management.
Experimental: Experimental group - same program as control group associated with the daily use of a hyperinsufflation technique (2 times per day during15 minutes, 5 days a week, for 2 years)
Other interventions: Standardized respiratory management program
Bronchial decluttering education, respiratory physiotherapy, specialized medical follow-up for 2 years
Other interventions: CoughAssist
self-administered mechanical in-exsufflation - CoughAssist (2 x 15 min per day, 5 days per week for 2 years)
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Effectiveness of a self-administered automated hyperinsufflation technique for 2 years, versus standard management, on respiratory infection risk within 2 years after randomization, in patients with MS.
Query!
Assessment method [1]
0
0
This will be evaluated by the incidence of lower respiratory infections requiring antibiotic therapy
Query!
Timepoint [1]
0
0
24 months
Query!
Secondary outcome [1]
0
0
Effect of COUGH-ASSIST on slowing the decline in respiratory function,
Query!
Assessment method [1]
0
0
This will be demonstrated by monitoring respiratory function by spirometry
Query!
Timepoint [1]
0
0
12 months and 24 months
Query!
Secondary outcome [2]
0
0
Functional effectiveness of COUGH-ASSIST
Query!
Assessment method [2]
0
0
By using the goal attainmentscaling method (GAS)
Query!
Timepoint [2]
0
0
12 months and 24 months
Query!
Secondary outcome [3]
0
0
Tolerance and compliance with COUGH-ASSIST,
Query!
Assessment method [3]
0
0
This will be evaluated via an online "patient reported outcomes form" and data readings from the internal memory of the COUGH-ASSIST
Query!
Timepoint [3]
0
0
24 months
Query!
Secondary outcome [4]
0
0
Effectiveness of COUGH-ASSIST in reducing the risk of serious respiratory infection
Query!
Assessment method [4]
0
0
This will be evaluate by the number of serious respiratory infection
Query!
Timepoint [4]
0
0
24 months
Query!
Eligibility
Key inclusion criteria
- Confirmed MS diagnosis (McDonald criteria)
- EDSS = 7
- Age greater than or equal to 18 years.
- Expiratory flow during a coughing effort (DEPtoux) ?4.5L / s.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- ENT and / or thoracic surgery less than 6 months old
- Progressive or past pneumothorax / pneumomediastinum
- Severe swallowing disorders.
- Inability to use the device under study
Query!
Study design
Purpose of the study
Supportive Care
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Unknown status
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
25/11/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/10/2022
Query!
Actual
Query!
Sample size
Target
84
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
France
Query!
State/province [1]
0
0
Haut De Seine
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Assistance Publique - Hôpitaux de Paris
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
In patients with neuromuscular disease, chest mobilization by hyperinsufflation slows
respiratory decline by almost 80% compared to controls, and prevents complications like
pneumonia, atelectasis and respiratory distress.
This insufflation technique improves the airway clearance and reduces the need for invasive
ventilation. It also improves CV and DEPtoux in patients with neuromuscular pathology
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04563832
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Jonathan LEVY, Dr
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+33 147107900
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04563832
Download to PDF